May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Evaluation of the Reproductibility of Repeated Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema
Author Affiliations & Notes
  • L. Malvitte
    Ophthalmology, University Hospital, Dijon, France
  • D. Gaucher
    Ophthalmology, University Hospital, Lariboisière, Paris, France
  • R. Tadayoni
    Ophthalmology, University Hospital, Lariboisière, Paris, France
  • A. Bron
    Ophthalmology, University Hospital, Dijon, France
  • C. Creuzot-Garcher
    Ophthalmology, University Hospital, Dijon, France
  • P. Massin
    Ophthalmology, University Hospital, Lariboisière, Paris, France
  • Footnotes
    Commercial Relationships  L. Malvitte, None; D. Gaucher, None; R. Tadayoni, None; A. Bron, None; C. Creuzot-Garcher, None; P. Massin, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3464. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Malvitte, D. Gaucher, R. Tadayoni, A. Bron, C. Creuzot-Garcher, P. Massin; Evaluation of the Reproductibility of Repeated Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3464.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To retrospectively evaluate the efficacy and the reproducibility of repeated intravitreal injections of 4 mg triamcinolone acetonide for refractory diffuse diabetic macular edema.

Methods: : This was a retrospective case series study. Forty-seven eyes of 36 patients with diabetic macular edema unresponsive to laser photocoagulation were included. All patients received at least two injections of 4 mg triamcinolone acetonide. The main outcome measures were the standardized changes in macular thickness (SCMT) measured by Optical Coherence Tomography and the evolution of visual acuity within the 6 months after each injection. Secondary outcomes were intraocular pressure, the rate of cataract surgery performed during the study and the mean time of re-injection

Results: : Forty-seven eyes received at least 2 injections; a third injection was performed in 30 eyes, a fourth one in 20 eyes and a fifth one in 12 eyes. The mean interval between injections was 9.1 months. The Central Macular Thickness (CMT) was reduced and visual acuity improved after all injections (p<0.05). The SCMT did not differ significantly whatever the number of injections. Cataract surgery was more frequent in eyes receiving more injections (p=0.001) whereas the increase in IOP was not related to the number of injections.

Conclusions: : In the long-term, repeated intravitreal injections of triamcinolone effectively reduced macular thickening due to diffuse diabetic macular edema and improved visual acuity. The rate of cataract surgery increased with the number of injections.

Keywords: diabetic retinopathy • edema • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×